China’s Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal

Nov 5 – Qyuns Therapeutics is licensing an early-stage antibody program to US biotech Caldera Therapeutics in a deal worth up to $750 million plus an upfront fee, the Hong Kong-listed firm said on Thursday. Here are some details: • Caldera gets exclusive worldwide rights to develop, manufacture, seek approval for and sell drug candidates from the program, while Qyuns will receive $30 million…

China’s Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal — Salem Radio Network News · Right
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead — Seeking Alpha · Right
China’s Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal — WNCY - 100.3 FM - Green Bay
China’s Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal — WTVB - Coldwater
Monte Rosa Therapeutics: Q3 Earnings Snapshot — Washington's Top News (WTOP)
Palvella Therapeutics: Q3 Earnings Snapshot — Washington's Top News (WTOP)
Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs — PR Newswire

Open True Mainstream to compare left, right, and center coverage